Background and aims Molnupiravir is a newer oral antiviral drug that has recently been
tested in COVID-19. We aim to conduct a systematic review of literature to find out the …

The development of effective antiviral therapy for COVID-19 is critical for those awaiting
vaccination, as well as for those who do not respond robustly to vaccination. This review …

Molnupiravir is an orally available antiviral drug candidate currently in phase III trials for the
treatment of patients with COVID-19. Molnupiravir increases the frequency of viral RNA …

The COVID-19 pandemic caused by severe acute respiratory syndrome coronavirus 2
(SARS-CoV-2) continually poses serious threats to global public health. The main protease …

The persistent pandemic of coronavirus disease 2019 (COVID-19) caused by severe acute
respiratory syndrome coronavirus 2 (SARS-CoV-2) and its variants accentuates the great …

Dear Editor, The ongoing SARS-CoV-2 pandemic continues to be a significant threat to
global health. First reported in November 2021, the Omicron variant (B. 1.1. 529) is more …

Starting from the MLPCN probe compound ML300, a structure-based optimization campaign
was initiated against the recent severe acute respiratory syndrome coronavirus (SARS-CoV …

Compound repurposing is an important strategy for the identification of effective treatment
options against SARS-CoV-2 infection and COVID-19 disease. In this regard, SARS-CoV-2 …

Nirmatrelvir (PF-07321332) is a nitrile-bearing small-molecule inhibitor that, in combination
with ritonavir, is used to treat infections by severe acute respiratory syndrome coronavirus-2 …

Recurring coronavirus outbreaks, such as the current COVID-19 pandemic, establish a
necessity to develop direct-acting antivirals that can be readily administered and are active …